Prostate Cancer | Specialty

Next-Generation AR Inhibitors Retain their Role in Nonmetastatic CRPC

January 18th 2021

Despite the availability of next-generation PET imaging modalities that can detect metastasis earlier, apalutamide, enzalutamide, and darolutamide remain the standard of care for patients with nonmetastatic castration-resistant prostate cancer who have a prostate-specific antigen doubling time of less than 10 months.

Pursuing New Paradigms in Prostate Cancer

January 14th 2021

In today’s episode, we had the pleasure of speaking with the faculty of a recent Institutional Perspectives in Cancer webinar on prostate cancer hosted by Yale Cancer Center.

UCLA, UCSF Gain FDA Approval for Prostate Cancer Imaging Technique

January 13th 2021

New prostate cancer imaging technique is a ‘game changer’ that should become the standard of care, say researchers from UCLA and UCSF who validated its effectiveness.

Dr. Schweizer on the Results of the HERO Trial in Prostate Cancer

January 13th 2021

Michael Schweizer, MD, discusses the results of the HERO trial in prostate cancer.

Dr. Gomella on the Role of Genetic Testing in Prostate Cancer

January 11th 2021

Leonard G. Gomella, MD, discusses the role of genetic testing in prostate cancer.

Addition of Darolutamide May Augment Standard Treatment for Localized, Very High-Risk Prostate Cancer

January 11th 2021

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the benefit achieved with standard-of-care radiation therapy plus androgen deprivation therapy with a luteinising hormone-releasing hormone analogue.

FDA Updates Label for Darolutamide in Nonmetastatic CRPC to Include OS Data

January 8th 2021

January 8, 2021 - The FDA has approved a supplemental new drug application to add overall survival and other secondary end point data from the phase 3 ARAMIS trial to the prescribing information for darolutamide for the treatment of patients with nonmetastatic prostate cancer.

Next-Generation Cytotoxic Therapy Moves Forward in mCRPC

January 7th 2021

VERU-111, a next-generation form of chemotherapy, has shown promising signs of efficacy as a treatment option for men with metastatic castration-resistant prostate cancer whose disease has progressed while receiving androgen receptor–targeting therapy.

Role for Somatic, Inherited Genetic Testing in Prostate Cancer Continues to Grow

January 3rd 2021

Leonard G. Gomella, MD, discusses the growing importance of genetic testing in prostate cancer.

Practice-Changing Trials Pave the Way for Novel Approaches in Metastatic Prostate Cancer

December 31st 2020

Joseph Kim, MD, discusses pivotal trials in metastatic prostate cancer, the rise of PARP inhibitors and novel combinations under investigation, and the promise of relugolix.